'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.
نویسنده
چکیده
[1] Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary athersclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50: 127–34. [2] Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC . Factors influencing the presence or absence of acute coronary thrombi in sudden ischaemic death. Eur Heart J 1989; 10: 203–8. [3] Starry HD, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions in the histological classification of atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1512–31. [4] Virmini R, Kolodgie D, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262–75. [5] Burke AP, Kolodgie D, Farb A. et al. Healed plaque ruptures and sudden coronary death. Evidence that sub-clinical rupture has a role in plaque progression. Circulation 2001; 103: 934–40. [6] Farb A, Burke AP, Tang ,AL et al. Coronary plaque erosion without rupture in to a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354–63. [7] Burke AP, Farb A, Malcolm GT et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276–82. [8] Leach IH, Blundell JW, Rowley JM, Turner DR.. Acute ischaemic lesions in death due to ischaemic heart disease: an autopsy study of 333 cases of out-of-hospital deaths. Eur Heart J 1995; 16: 1181–5. [9] Arbustini E, Dal Bello B, Morbinni P et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999; 82: 269–72. [10] Henriques de Gouveia R, van der Wal AC, van der Loos CM, Becker AE. . Sudden unexpected death in young adults. Discrepancies between initiation of acute plaque complications and the onset of acute coronary death. Eur Heart J 2002; 23: 1433–1440.
منابع مشابه
Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
The role played by glycoprotein (GP) IIb/IIIa inhibitors has continuously evolved from the initial introduction in mid 90 s until the most recent guidelines for treating acute coronary syndromes, and competed with a wider use of ADP inhibitors and novel anticoagulant drugs, to the extent that they stepped down from class I to class II recommendation in the routine setting of acute coronary synd...
متن کاملWill diabetes save the platelet blockers?
More than 30 000 patients have been enrolled in trials assessing the efficacy of glycoprotein (GP) IIb/IIIa inhibitors in unstable angina (UA) or non– ST-segment elevation MI (NSTEMI). The initial trials demonstrated that the use of a GP IIb/IIIa inhibitor resulted in a significant decrease in the rate of death or nonfatal myocardial infarction.1,2 More recently, however, the GP IIb/IIIa inhibi...
متن کاملGlycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction.
Glycoprotein (GP) IIb/IIIa inhibitors have been extensively studied in the setting of percutaneous coronary intervention (PCI) and in the management of non-ST-segment elevation acute coronary syndromes. However, the use of GP IIb/IIIa inhibitors is less well established in the setting of acute ST-segment elevation myocardial infarction (MI). Multiple nonrandomized studies suggest that combinati...
متن کاملNICE appraisals and cardiology: glycoprotein IIb/IIIa inhibitors and acute coronary syndromes.
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
متن کاملPlatelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
BACKGROUND Diabetes mellitus is a major risk factor for adverse outcomes after acute coronary syndromes (ACS). Because this disease may be associated with increased platelet aggregation, we investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb/IIIa receptor inhibition. METHODS AND RESULTS We performed a meta-analysis of the diabetic popu...
متن کاملCurrent role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
CONTEXT The central role of platelet-rich thrombus in the pathogenesis of acute coronary syndromes (ACSs) is well-known. Glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor antagonists are potent inhibitors of platelet function that may be expected to affect favorably the natural history of ACSs. OBJECTIVE To define the optimal role of Gp IIb/IIIa inhibitors in treatment strategies for ACSs. DATA ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- European heart journal
دوره 23 18 شماره
صفحات -
تاریخ انتشار 2002